Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Testimony on accelerated approval.

Carlton Hogan

    GMHC Treatment Issues : the Gay Men'S Health Crisis Newsletter of Experimental AIDS Therapies
    |January 14, 2004
    PubMed
    Summary
    This summary is machine-generated.

    Carlton Hogan warned the FDA in 1994 about risks of new drugs without post-market safety tracking. His concerns about drug toxicity and manufacturer accountability remain relevant for antiviral therapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Independent review.

    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies·2002
    Same author

    AIDS clinical trials: ethical and design issues.

    Journal international de bioethique = International journal of bioethics·2001
    Same journal

    Reading Durban.

    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies·2009
    Same journal

    The body habitus in Durban.

    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies·2009
    Same journal

    Success in preventing mother-to-child transmission not a reality at all.

    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies·2009
    Same journal

    What happened in Durban? A South African perspective.

    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies·2009
    Same journal

    Migration and HIV in Africa: challenges and recommendations.

    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies·2009
    Same journal

    HIV lipodystrophy: where are we after ten years?

    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies·2009
    See all related articles

    Area of Science:

    • Pharmacovigilance
    • Public Health Policy
    • Antiviral Drug Development

    Background:

    • Carlton Hogan's 1994 testimony highlighted the critical need for robust post-marketing surveillance of antiviral drugs.
    • AIDS activists echoed Hogan's concerns in 2003, emphasizing the necessity of monitoring long-term drug toxicity and manufacturer compliance.
    • Hogan's foresight is evident, addressing issues that became prominent with the advent of effective antiretroviral therapy and its associated complications like lipodystrophy.

    Discussion:

    • The testimony underscores the persistent challenges in drug safety monitoring, particularly for treatments with long-term or delayed adverse effects.
    • It raises questions about regulatory agency authority and the enforcement of post-approval drug studies.
    • The historical context reveals a critical juncture in HIV/AIDS treatment activism and drug safety advocacy.

    Related Experiment Videos

    Key Insights:

    • Early warnings regarding the lack of rigorous methods for detecting late-emerging drug toxicity were largely unheeded.
    • Drug manufacturers' post-approval study commitments and regulatory enforcement mechanisms were identified as inadequate.
    • The emergence of complications like lipodystrophy validated the concerns about insufficient post-marketing surveillance.

    Outlook:

    • Hogan's testimony serves as a crucial historical reference for ongoing debates on drug safety and regulatory oversight.
    • It emphasizes the importance of proactive pharmacovigilance systems to protect patient health.
    • The need for stronger regulatory frameworks and accountability for pharmaceutical companies remains a key public health priority.